Cargando…

Current and emerging drug targets in heart failure treatment

After initial strategies targeting inotropism and congestion, the neurohormonal interpretative model of heart failure (HF) pathophysiology has set the basis for current pharmacological management of HF, as most of guideline recommended drug classes, including beta-blockers, angiotensin-converting en...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ghionzoli, Nicolò, Gentile, Francesco, Del Franco, Anna Maria, Castiglione, Vincenzo, Aimo, Alberto, Giannoni, Alberto, Burchielli, Silvia, Cameli, Matteo, Emdin, Michele, Vergaro, Giuseppe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9197912/ https://www.ncbi.nlm.nih.gov/pubmed/34273070 http://dx.doi.org/10.1007/s10741-021-10137-2

Ejemplares similares

Pathophysiological Rationale and Clinical Evidence for Neurohormonal Modulation in Heart Failure with Preserved Ejection Fraction
por: Castiglione, Vincenzo, et al.
Publicado: (2023)

Biomarkers for the diagnosis and management of heart failure
por: Castiglione, Vincenzo, et al.
Publicado: (2021)

Intact fibroblast growth factor 23 in heart failure with reduced and mildly reduced ejection fraction
por: Vergaro, Giuseppe, et al.
Publicado: (2023)

Central and Obstructive Apneas in Heart Failure With Reduced, Mid-Range and Preserved Ejection Fraction
por: Borrelli, Chiara, et al.
Publicado: (2019)

The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction
por: Aimo, Alberto, et al.
Publicado: (2021)

Noncardiac Versus Cardiac Mortality in Heart Failure With Preserved, Midrange, and Reduced Ejection Fraction
por: Vergaro, Giuseppe, et al.
Publicado: (2019)

Bidirectional Relationship Between Cancer and Heart Failure: Insights on Circulating Biomarkers
por: Chianca, Michela, et al.
Publicado: (2022)

Biomarkers of HFpEF: Natriuretic Peptides, High-Sensitivity Troponins and Beyond
por: Morfino, Paolo, et al.
Publicado: (2022)

Monoclonal antibodies and amyloid removal as a therapeutic strategy for cardiac amyloidosis
por: Emdin, Michele, et al.
Publicado: (2023)

Central Apneas Are More Detrimental in Female Than in Male Patients With Heart Failure
por: Gentile, Francesco, et al.
Publicado: (2022)

Transthyretin Stabilizers and Seeding Inhibitors as Therapies for Amyloid Transthyretin Cardiomyopathy
por: Morfino, Paolo, et al.
Publicado: (2023)

Prognostic Value of sST2 in Heart Failure
por: Sciatti, Edoardo, et al.
Publicado: (2023)

Haemodynamic forces predicting remodelling and outcome in patients with heart failure treated with sacubitril/valsartan
por: Fabiani, Iacopo, et al.
Publicado: (2023)

Role of Imaging in Cardiomyopathies
por: Castiglione, Vincenzo, et al.
Publicado: (2023)

Molecular Autopsy of Sudden Cardiac Death in the Genomics Era
por: Castiglione, Vincenzo, et al.
Publicado: (2021)

Contribution of the Lung to the Genesis of Cheyne‐Stokes Respiration in Heart Failure: Plant Gain Beyond Chemoreflex Gain and Circulation Time
por: Giannoni, Alberto, et al.
Publicado: (2019)

Biopsy Evidence of Sequential Transthyretin and Immunoglobulin Light-Chain Cardiac Amyloidosis in the Same Patient
por: Vergaro, Giuseppe, et al.
Publicado: (2021)

The Journey of Human Transthyretin: Synthesis, Structure Stability, and Catabolism
por: Sanguinetti, Chiara, et al.
Publicado: (2022)

Abdominal Fat Biopsy for the Diagnosis of Cardiac Amyloidosis
por: Aimo, Alberto, et al.
Publicado: (2020)

Novel Drug Targets for Central Apneas in Heart Failure: On the Road
por: Borrelli, Chiara, et al.
Publicado: (2021)

Cardiovascular toxicity from therapies for light chain amyloidosis
por: Morfino, Paolo, et al.
Publicado: (2023)

Prognostic value of reverse remodelling criteria in heart failure with reduced or mid‐range ejection fraction
por: Aimo, Alberto, et al.
Publicado: (2021)

Tissue Characterization in Cardiac Amyloidosis
por: Musetti, Veronica, et al.
Publicado: (2022)

Valve disease in cardiac amyloidosis: an echocardiographic score
por: Aimo, Alberto, et al.
Publicado: (2023)

Cardiogenic shock and acute kidney injury: the rule rather than the exception
por: Ghionzoli, N, et al.
Publicado: (2020)

Building medical knowledge from real world registries: The case of heart failure
por: Aimo, Alberto, et al.
Publicado: (2018)

Rituximab as a novel treatment for heart failure: evidence from a case series
por: Aimo, Alberto, et al.
Publicado: (2019)

The role of non-invasive imaging modalities in cardiac allograft vasculopathy: an updated focus on current evidences
por: Sciaccaluga, C, et al.
Publicado: (2021)

Subclinical cardiac damage in cancer patients before chemotherapy
por: Fabiani, Iacopo, et al.
Publicado: (2021)

Atrial amyloidosis: mechanisms and clinical manifestations
por: Vergaro, Giuseppe, et al.
Publicado: (2022)

Safety and Efficacy of Amiodarone in a Patient With COVID-19
por: Castaldo, Nadia, et al.
Publicado: (2020)

Prediction of the Chemoreflex Gain by Common Clinical Variables in Heart Failure
por: Mirizzi, Gianluca, et al.
Publicado: (2016)

Oxidative stress and inflammation: determinants of anthracycline cardiotoxicity and possible therapeutic targets
por: Fabiani, Iacopo, et al.
Publicado: (2020)

Renin profiling predicts neurohormonal response to sacubitril/valsartan
por: Vergaro, Giuseppe, et al.
Publicado: (2020)

Management of heart failure with preserved ejection fraction: from neurohormonal antagonists to empagliflozin
por: Aimo, Alberto, et al.
Publicado: (2022)

Treatment of cardiac fibrosis: from neuro-hormonal inhibitors to CAR-T cell therapy
por: Morfino, Paolo, et al.
Publicado: (2022)

Creatine deficiency and heart failure
por: Del Franco, Annamaria, et al.
Publicado: (2021)

The ergoreflex: how the skeletal muscle modulates ventilation and cardiovascular function in health and disease
por: Aimo, Alberto, et al.
Publicado: (2021)

Prognostic Benefit of New Drugs for HFrEF: A Systematic Review and Network Meta-Analysis
por: Pagnesi, Matteo, et al.
Publicado: (2022)

Cardiac protection by pirfenidone after myocardial infarction: a bioinformatic analysis
por: Aimo, Alberto, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fnps4rbd44871l82k7pkf8gimk